FDA approves asthma treatment Spiriva Respimat
16 September 2015 | By Victoria White
It is approved by the FDA for the long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older...
List view / Grid view
16 September 2015 | By Victoria White
It is approved by the FDA for the long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older...
15 September 2015 | By Victoria White
Data from secondary analyses of Phase III trials show Abasaglar (insulin glargine) demonstrated safety and efficacy outcomes similar to Lantus in diabetes...
1 September 2015 | By Charlotte Batchelor
Four grants will be awarded to independent research projects, focused on improving patient outcomes in thromboembolic diseases
27 August 2015 | By Nick Jackson
Synjardy approval was based on multiple clinical trials showing reductions in blood glucose versus placebo...
20 August 2015 | By Victoria White
Boehringer Ingelheim and Lilly have announced positive top-line results from a clinical study investigating cardiovascular (CV) outcomes for Jardiance...
17 August 2015 | By Victoria White
New data show Spiolto Respimat provides consistent, clinically meaningful improvements in quality of life versus placebo in patients COPD...
28 July 2015 | By Victoria White
Boehringer Ingelheim has entered an exclusive and collaboration agreement for the development and global commercialisation rights of HM61713...
24 July 2015 | By Victoria White
An independent expert review of alteplase has provided a firm reassurance that it is safe and effective for use up to 4.5 hours after the onset of symptoms...
16 July 2015 | By
Boehringer Ingelheim has welcomed new international treatment guidelines for IPF which suggest that clinicians use Ofev in patients with the disease...
6 July 2015 | By Victoria White
Results from the LUX-Lung 8 Trial demonstrate that afatinib resulted in superior progression-free survival and overall survival compared to erlotinib...
2 July 2015 | By Victoria White
Boehringer Ingelheim today announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in a number of European countries...
1 July 2015 | By Victoria White
Vitae has announced top-line efficacy results from the metformin arm of a trial of BI187004/VTP-34072 in the treatment of patients with type 2 diabetes...
22 June 2015 | By Victoria White
Results from an interim analysis of a Phase III study demonstrate that idarucizumab immediately reversed the anticoagulant effect of dabigatran...
16 June 2015 | By Victoria White
Results from a healthy volunteer study investigating the reversal of the anticoagulant effect of Pradaxa by idarucizumab have been published...
3 June 2015 | By Victoria White
Boehringer Ingelheim’s VARGATEF in combination with docetaxel has been recommended for use within the National Health Service (NHS) in England and Wales...